Literature DB >> 23376461

Expression and purification of an immunogenic dengue virus epitope using a synthetic consensus sequence of envelope domain III and Saccharomyces cerevisiae.

Ngoc-Luong Nguyen1, Jung-Mi Kim, Jin-Ah Park, Seung-Moon Park, Yong-Suk Jang, Moon-Sik Yang, Dae-Hyuk Kim.   

Abstract

A synthetic consensus gene was designed based on residues of the amino acid sequences of dengue envelope domain III (scEDIII) from all four serotypes, and codon optimization for expression was conducted using baker's yeast, Saccharomyces cerevisiae. The synthetic gene was cloned into a yeast episomal expression vector, pYEGPD-TER, which was designed to direct cloned gene expression using the glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter, a functional signal peptide of the amylase 1A protein from rice, and the GAL7 terminator. PCR and back-transformation into Escherichia coli confirmed the presence of the scEDIII gene-containing plasmid in the transformants. Northern blot analysis showed the presence of the scEDIII-specific transcript. Western blot analysis indicated that expressed scEDIII, with mobility similar to purified EDIII from E. coli, was successfully secreted into the culture media. Quantitative ELISA revealed that the recombinant scEDIII comprised approximately 0.1-0.6% of cell-free extract. In addition, 0.1-0.6 mg of scEDIII protein per liter of culture filtrate was detected on day 1 and peaked on day 3 after cultivation. The secreted scEDIII protein can be purified to ≥90% purity with 85% recovery using a simple ion-exchange FPLC followed by molecular weight cut-off. Upon administration of the purified protein to mice, mouse sera contained antibodies that were specific to all four serotypes of dengue virus. Moreover, a balanced immune response against all four serotypes was observed, suggesting that it may be possible to develop an effective tetravalent dengue vaccine using S. cerevisiae.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23376461     DOI: 10.1016/j.pep.2013.01.009

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  7 in total

1.  Interaction between hypoviral-regulated fungal virulence factor laccase3 and small heat shock protein Hsp24 from the chestnut blight fungus Cryphonectria parasitica.

Authors:  Jeesun Chun; Yo-Han Ko; Dae-Hyuk Kim
Journal:  J Microbiol       Date:  2021-11-26       Impact factor: 3.422

2.  Evaluation of cell-surface displayed synthetic consensus dengue EDIII cells as a potent oral vaccine candidate.

Authors:  Jyotiranjan Bal; Hee-Young Jung; Luong Ngoc Nguyen; Jisang Park; Yong-Suk Jang; Dae-Hyuk Kim
Journal:  Microb Cell Fact       Date:  2018-09-14       Impact factor: 5.328

Review 3.  Recent Developments in Recombinant Protein-Based Dengue Vaccines.

Authors:  Nagesh K Tripathi; Ambuj Shrivastava
Journal:  Front Immunol       Date:  2018-08-23       Impact factor: 7.561

4.  Reactivity of human antisera to codon optimized SARS-CoV2 viral proteins expressed in Escherichia coli.

Authors:  Yee-Huan Toh; Yu-Weng Huang; Yo-Chen Chang; Yi-Ting Chen; Ya-Ting Hsu; Guang-Huey Lin
Journal:  Tzu Chi Med J       Date:  2021-03-09

5.  Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine.

Authors:  Hui Zhao; Tao Jiang; Xi-Zhen Zhou; Yong-Qiang Deng; Xiao-Feng Li; Shui-Ping Chen; Shun-Ya Zhu; Xi Zhou; E-De Qin; Cheng-Feng Qin
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

6.  Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate.

Authors:  Jyotiranjan Bal; Nguyen Ngoc Luong; Jisang Park; Ki-Duk Song; Yong-Suk Jang; Dae-Hyuk Kim
Journal:  Microb Cell Fact       Date:  2018-02-16       Impact factor: 5.328

7.  Expression of an immunocomplex consisting of Fc fragment fused with a consensus dengue envelope domain III in Saccharomyces cerevisiae.

Authors:  Kum-Kang So; Jeesun Chun; Nguyen Ngoc Luong; Hee-Won Seo; Dae-Hyuk Kim
Journal:  Biotechnol Lett       Date:  2021-07-10       Impact factor: 2.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.